GW Pharmaceuticals PLC’s (NASDAQ: GWPH) reported fiscal fourth-quarter financial results that were pretty grim. Quarterly revenue collapsed 70%, to $2.1 million, and surging expenses tied to researching marijuana medicines resulted in a net loss of $21.8 million. The company’s full-fiscal-year revenue was $13.3 million, down about 64% from last year, and its net loss was $82.2 million